Astellas Pharma, Sangamo Therapeutics, Inc. sign licensing agreement for genomic medicines Sangamo will receive a $20m upfront license fee and is eligible to earn up to $1.3bn in additional licensed target fees and milestone payments across all five potential disease targets, along with tiered royalties Read more: https://lnkd.in/eX7jHHzV #pharmanews #pharmaceuticalindustry #drugresearch #genomics #researchanddevelopment #r&d #worldpharma #druglicensing
